Pulmatrix agreed to merge with Eos SENOLYTIX; the combined company will operate as Eos SENOLYTIX and is expected to trade on a national exchange. Eos SENOLYTIX develops therapies aimed at improving healthspan by restoring mitochondrial function, indicating a strategic focus on senolytic/mitochondrial therapeutics. No financial terms, timelines, or expected pro forma ownership disclosed.
Pulmatrix agreed to merge with Eos SENOLYTIX; the combined company will operate as Eos SENOLYTIX and is expected to trade on a national exchange. Eos SENOLYTIX develops therapies aimed at improving healthspan by restoring mitochondrial function, indicating a strategic focus on senolytic/mitochondrial therapeutics. No financial terms, timelines, or expected pro forma ownership disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
